Appraisal for the Potential of Viral and Nonviral Vectors in Gene Therapy: A Review
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Over the past few decades, gene therapy has gained immense importance in medical research as a promising treatment strategy for diseases such as cancer, AIDS, Alzheimer’s disease, and many genetic disorders. When a gene needs to be delivered to a target cell inside the human body, it has to pass a large number of barriers through the extracellular and intracellular environment. This is why the delivery of naked genes and nucleic acids is highly unfavorable, and gene delivery requires suitable vectors that can carry the gene cargo to the target site and protect it from biological degradation. To date, medical research has come up with two types of gene delivery vectors, which are viral and nonviral vectors. The ability of viruses to protect transgenes from biological degradation and their capability to efficiently cross cellular barriers have allowed gene therapy research to develop new approaches utilizing viruses and their different genomes as vectors for gene delivery. Although viral vectors are very efficient, science has also come up with numerous nonviral systems based on cationic lipids, cationic polymers, and inorganic particles that provide sustainable gene expression without triggering unwanted inflammatory and immune reactions, and that are considered nontoxic. In this review, we discuss in detail the latest data available on all viral and nonviral vectors used in gene delivery. The mechanisms of viral and nonviral vector-based gene delivery are presented, and the advantages and disadvantages of all types of vectors are also given.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biodegradable polymers as biomaterials
Nair, L. S., & Laurencin, C. T. (2007) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.05.017 · Cited by 4,416
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173 · cited 1×
“The needle injection technique was first reported by Wolf and coworkers in 1990, who administered an intramuscular injection of naked DNA directly into myofibers of mouse muscle [53].”
MethodToxicity of cationic lipids and cationic polymers in gene delivery
Lv, H., Zhang, S., Wang, B., Cui, S., & Yan, J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.014 · Cited by 2,286
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854 · cited 1×
“The genomic insertion point of these viruses was different from MLV vectors; thus, they showed a decreased occurrence of genotoxicity [27,28].”
BackgroundViral vector platforms within the gene therapy landscape
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00487-6 · Cited by 1,404
Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration
Wu, X., Li, Y., Crise, B., & Burgess, S. M. (2003) · Science · doi:10.1126/science.1083413 · Cited by 1,305 · cited 1×
“The genomic insertion point of these viruses was different from MLV vectors; thus, they showed a decreased occurrence of genotoxicity [27,28].”
BackgroundBiodegradable synthetic polymers: Preparation, functionalization and biomedical application
Tian, H., Tang, Z., Zhuang, X., Chen, X., & Jing, X. (2012) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2011.06.004 · Cited by 1,293 · cited 1×
“Scientists and medical researchers are focusing on ways to incorporate different functional groups and chemical moieties in synthetic polymers to prepare them for targeted drug and gene delivery [93].”
BackgroundThe Smart Drug Delivery System and Its Clinical Potential
Liu, D., Yang, F., Xiong, F., & Gu, N. (2016) · Theranostics · doi:10.7150/thno.14858 · Cited by 1,066
Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review
Hossen, S., Hossain, M. K., Basher, M. K., Mia, M. N. H., Rahman, M. T., & Uddin, M. J. (2019) · Journal of Advanced Research · doi:10.1016/j.jare.2018.06.005 · Cited by 998
Self-citationGene therapy clinical trials worldwide to 2017: An update
Ginn, S. L., Amaya, A. K., Alexander, I. E., Edelstein, M., & Abedi, M. R. (2018) · The Journal of Gene Medicine · doi:10.1002/jgm.3015 · Cited by 903 · cited 1×
“According to The Journal of Gene Medicine, up until November 2017, more than 68% of the clinical trials conducted on gene therapy utilized viruses as vectors for gene delivery [5].”
Background
Research works printed but not linked: 118
- Hill, 2016, Overcoming gene-delivery hurdles: Physiological considerations for nonviral vectors, Trends Biotechnol., 34, 91, 10.1016/j.tibtech.2015.11.004 · DOI · Paper page
- Zhang, 2012, In vivo gene delivery by nonviral vectors: Overcoming hurdles?, Mol. Ther., 20, 1298, 10.1038/mt.2012.79 · DOI · Paper page
- Kotterman, 2015, Viral vectors for gene therapy: Translational and clinical outlook, Annu. Rev. Biomed. Eng., 17, 63, 10.1146/annurev-bioeng-071813-104938 · DOI · Paper page
- Lukashev, 2016, Viral vectors for gene therapy: Current state and clinical perspectives, Biochemistry, 81, 700
- Desfarges, S., and Ciuffi, A. (2012). Viral integration and consequences on host gene expression. Viruses: Essential Agents of Life, Springer. · DOI
- Crenshaw, B.J., Jones, L.B., Bell, C.R., Kumar, S., and Matthews, Q.L. (2019). Perspective on adenoviruses: Epidemiology, pathogenicity, and gene therapy. Biomedicines, 7. · DOI
- Giacca, M. (2010). Introduction to gene therapy. Gene Therapy, Springer. · DOI
- Tsai, 2000, Adenovirus-mediated transfer of regulable gene expression, Curr. Opin. Mol. Ther., 2, 515
- Lyons, 2006, Adenovirus type 5 interactions with human blood cells may compromise systemic delivery, Mol. Ther., 14, 118, 10.1016/j.ymthe.2006.01.003 · DOI
- Raper, 2003, Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer, Mol. Genet. Metab., 80, 148, 10.1016/j.ymgme.2003.08.016 · DOI · Paper page
- Bandara, 2021, Potential of helper-dependent Adenoviral vectors in CRISPR-cas9-mediated lung gene therapy, Cell Biosci., 11, 145, 10.1186/s13578-021-00662-w · DOI
- Cao, 2020, A helper-dependent adenoviral vector rescues CFTR to wild-type functional levels in cystic fibrosis epithelial cells harbouring class I mutations, Eur. Respir. J., 56, 2000205, 10.1183/13993003.00205-2020 · DOI
- Ricobaraza, A., Gonzalez-Aparicio, M., Mora-Jimenez, L., Lumbreras, S., and Hernandez-Alcoceba, R. (2020). High-capacity adenoviral vectors: Expanding the scope of gene therapy. Int. J. Mol. Sci., 21. · DOI
- Singh, 2019, Adenoviral vector-based vaccines and gene therapies: Current status and future prospects, Adenoviruses, 4, 53
- Chandler, 2016, Gene therapy for metabolic diseases, Transl. Sci. Rare Dis., 1, 73
- Pereboev, 2004, Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule, Mol. Ther., 9, 712, 10.1016/j.ymthe.2004.02.006 · DOI
- Rivera, 2007, Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer, Int. J. Cancer, 120, 935, 10.1002/ijc.22338 · DOI
- Matthews, 2006, Genetic incorporation of a herpes simplex virus type 1 thymidine kinase and firefly luciferase fusion into the adenovirus protein IX for functional display on the virion, Mol. Imaging, 5, 7290.2006.00029, 10.2310/7290.2006.00029 · DOI
- Tang, 2008, Derivation of a triple mosaic adenovirus based on modification of the minor capsid protein IX, Virology, 377, 391, 10.1016/j.virol.2008.04.023 · DOI
- Cattoglio, 2010, High-definition mapping of retroviral integration sites identifies active regulatory elements in human multipotent hematopoietic progenitors, Blood J. Am. Soc. Hematol., 116, 5507
- Ghosh, 2020, Viral vector systems for gene therapy: A comprehensive literature review of progress and biosafety challenges, Appl. Biosaf., 25, 7, 10.1177/1535676019899502 · DOI · Paper page
- Vogt, 2012, Retroviral oncogenes: A historical primer, Nat. Rev. Cancer, 12, 639, 10.1038/nrc3320 · DOI · Paper page
- Montini, 2006, Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration, Nat. Biotechnol., 24, 687, 10.1038/nbt1216 · DOI · Paper page
- Ramezani, 2002, Overview of the HIV-1 lentiviral vector system, Curr. Protoc. Mol. Biol., 60, 16.21. 11
- Collins, 2017, Viral vector biosafety in laboratory animal research, Comp. Med., 67, 215
- Romano, 2012, Development of safer gene delivery systems to minimize the risk of insertional mutagenesis-related malignancies: A critical issue for the field of gene therapy, Int. Sch. Res. Not., 2012, 616310
- David, 2017, Viral vectors: The road to reducing genotoxicity, Toxicol. Sci., 155, 315, 10.1093/toxsci/kfw220 · DOI · Paper page
- Montes, 2005, Viral vectors in gene therapy. Advantages of the adenoassociated vectors, Rev. Gastroenterol. Mex., 70, 192
- Gao, 2002, Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy, Proc. Natl. Acad. Sci. USA, 99, 11854, 10.1073/pnas.182412299 · DOI · Paper page
- Conrad, S.J., and Liu, J. (2019). Poxviruses as gene therapy vectors: Generating Poxviral vectors expressing therapeutic transgenes. Viral Vectors for Gene Therapy, Springer. · DOI
- Mell, 2017, Phase I trial of intravenous oncolytic vaccinia virus (GL-ONC1) with cisplatin and radiotherapy in patients with locoregionally advanced head and neck carcinoma, Clin. Cancer Res., 23, 5696, 10.1158/1078-0432.CCR-16-3232 · DOI
- Kantor, 2014, Methods for gene transfer to the central nervous system, Adv. Genet., 87, 125, 10.1016/B978-0-12-800149-3.00003-2 · DOI · Paper page
- Ono, C., Okamoto, T., Abe, T., and Matsuura, Y. (2018). Baculovirus as a tool for gene delivery and gene therapy. Viruses, 10. · DOI · Paper page
- Weklak, D., Pembaur, D., Koukou, G., Jönsson, F., Hagedorn, C., and Kreppel, F. (2021). Genetic and Chemical Capsid Modifications of Adenovirus Vectors to Modulate Vector–Host Interactions. Viruses, 13. · DOI
- Liu, 2018, Current Status of Nonviral Vectors for Gene Therapy in China, Hum. Gene Ther., 29, 110, 10.1089/hum.2017.226 · DOI
- Hidai, C., and Kitano, H. (2018). Nonviral gene therapy for cancer: A review. Diseases, 6. · DOI
- Jones, 2015, Contemporary approaches for nonviral gene therapy, Discov. Med., 19, 447
- Guy, 2005, Physical methods for gene transfer: Improving the kinetics of gene delivery into cells, Adv. Drug Deliv. Rev., 57, 733, 10.1016/j.addr.2004.12.007 · DOI · Paper page
- Jinturkar, K.A., Rathi, M.N., and Misra, A. (2011). Gene delivery using physical methods. Challenges in Delivery of Therapeutic Genomics and Proteomics, Elsevier. · DOI
- Hosokawa, 2009, Gene delivery process in a single animal cell after femtosecond laser microinjection, Appl. Surf. Sci., 255, 9880, 10.1016/j.apsusc.2009.04.111 · DOI
- King, R. (2004). Gene delivery to mammalian cells by microinjection. Gene Delivery to Mammalian Cells, Springer.
- Lui, 2001, Systemic production of IL-12 by naked DNA mediated gene transfer: Toxicity and attenuation of transgene expression in vivo, J. Gene Med., 3, 384, 10.1002/jgm.201 · doi:10.1002/jgm.201
- Springer, 2001, Gene delivery to muscle, Curr. Protoc. Hum. Genet., 31, 13.14. 11
- Wendell, D.M., Hemond, B.D., Hogan, N.C., Taberner, A.J., and Hunter, I.W. (September, January 30). The effect of jet parameters on jet injection. Proceedings of the 2006 International Conference of the IEEE Engineering in Medicine and Biology Society, New York, NY, USA. · DOI
- Fargnoli, 2014, A needleless liquid jet injection delivery method for cardiac gene therapy: A comparative evaluation versus standard routes of delivery reveals enhanced therapeutic retention and cardiac specific gene expression, J. Cardiovasc. Transl. Res., 7, 756, 10.1007/s12265-014-9593-1 · DOI
- Lysakowski, 2003, A needle-free jet-injection system with lidocaine for peripheral intravenous cannula insertion: A randomized controlled trial with cost-effectiveness analysis, Anesth. Analg., 96, 215
- Chuang, 2003, Gene therapy for bladder pain with gene gun particle encoding pro-opiomelanocortin cDNA, J. Urol., 170, 2044, 10.1097/01.ju.0000092945.76827.47 · doi:10.1097/01.ju.0000092945.76827.47
- Dutta, 2021, Nonviral gene therapy: Technology and application, Res. J. Sci. Technol., 13, 13, 10.5958/2349-2988.2021.00003.6 · doi:10.5958/2349-2988.2021.00003.6
- Neumann, 1982, Gene transfer into mouse lyoma cells by electroporation in high electric fields, EMBO J., 1, 841, 10.1002/j.1460-2075.1982.tb01257.x · DOI · Paper page
- Titomirov, 1991, In vivo electroporation and stable transformation of skin cells of newborn mice by plasmid DNA, Biochim. Et Biophys. Acta (BBA)-Gene Struct. Expr., 1088, 131, 10.1016/0167-4781(91)90162-F · DOI · Paper page
- Heller, 2006, In vivo electroporation for gene therapy, Hum. Gene Ther., 17, 890, 10.1089/hum.2006.17.890 · DOI · Paper page
- Young, 2015, Electroporation-mediated gene delivery, Adv. Genet., 89, 49, 10.1016/bs.adgen.2014.10.003 · DOI · Paper page
- Lambricht, 2016, Clinical potential of electroporation for gene therapy and DNA vaccine delivery, Expert Opin. Drug Deliv., 13, 295, 10.1517/17425247.2016.1121990 · DOI · Paper page
- Aslan, 2006, Nucleofection-based ex vivo nonviral gene delivery to human stem cells as a platform for tissue regeneration, Tissue Eng., 12, 877, 10.1089/ten.2006.12.877 · DOI
- Delalande, 2012, Ultrasound and microbubble-assisted gene delivery: Recent advances and ongoing challenges, Ther. Deliv., 3, 1199, 10.4155/tde.12.100 · DOI
- Liang, 2010, Sonoporation, drug delivery, and gene therapy, Proc. Inst. Mech. Eng. Part H J. Eng. Med., 224, 343, 10.1243/09544119JEIM565 · DOI · Paper page
- Unger, 2001, Local drug and gene delivery through microbubbles, Prog. Cardiovasc. Dis., 44, 45, 10.1053/pcad.2001.26443 · DOI · Paper page
- Suda, 2007, Hydrodynamic gene delivery: Its principles and applications, Mol. Ther., 15, 2063, 10.1038/sj.mt.6300314 · DOI · Paper page
- Fabre, 2008, Hydrodynamic gene delivery to the pig liver via an isolated segment of the inferior vena cava, Gene Ther., 15, 452, 10.1038/sj.gt.3303079 · DOI
- Du, 2018, Advanced physical techniques for gene delivery based on membrane perforation, Drug Deliv., 25, 1516, 10.1080/10717544.2018.1480674 · DOI
- Zhang, 2010, Gene delivery in three-dimensional cell cultures by superparamagnetic nanoparticles, ACS Nano, 4, 4733, 10.1021/nn9018812 · DOI
- Meacham, 2014, Physical methods for intracellular delivery: Practical aspects from laboratory use to industrial-scale processing, J. Lab. Autom., 19, 1, 10.1177/2211068213494388 · DOI
- Li, 2008, Enhanced thoracic gene delivery by magnetic nanobead-mediated vector, J. Gene Med. A Cross-Discip. J. Res. Sci. Gene Transf. Its Clin. Appl., 10, 897
- Prosen, 2014, Mcam silencing with RNA interference using magnetofection has antitumor effect in murine melanoma, Mol. Ther.-Nucleic Acids, 3, e205, 10.1038/mtna.2014.56 · DOI
- Li, 2009, Nanoparticle delivery of anti-metastatic NM23-H1 gene improves chemotherapy in a mouse tumor model, Cancer Gene Ther., 16, 423, 10.1038/cgt.2008.97 · doi:10.1038/cgt.2008.97
- Liu, 2002, Noninvasive gene delivery to the liver by mechanical massage, Hepatology, 35, 1314, 10.1053/jhep.2002.33467 · DOI
- Liu, 2004, Mechanism of liver gene transfer by mechanical massage, Mol. Ther., 9, 452, 10.1016/j.ymthe.2003.12.003 · doi:10.1016/j.ymthe.2003.12.003
- Wang, 2013, Non-viral gene delivery methods, Curr. Pharm. Biotechnol., 14, 46
- Khalid, 2017, Polymeric nanoparticles: Promising platform for drug delivery, Int. J. Pharm., 528, 675, 10.1016/j.ijpharm.2017.06.052 · DOI · Paper page
- Rose, 2017, Phosphonium polymers for gene delivery, Polym. Chem., 8, 353, 10.1039/C6PY01855F · DOI
- Nóbrega, C., Mendonça, L., and Matos, C.A. (2020). A Handbook of Gene and Cell Therapy, Springer. · DOI
- Park, 2006, Current status of polymeric gene delivery systems, Adv. Drug Deliv. Rev., 58, 467, 10.1016/j.addr.2006.03.007 · DOI · Paper page
- Schubert, 2012, Branched and linear poly (ethylene imine)-based conjugates: Synthetic modification, characterization, and application, Chem. Soc. Rev., 41, 4755, 10.1039/c2cs35146c · DOI · Paper page
- Liu, 2010, Hydrophobic modifications of cationic polymers for gene delivery, Prog. Polym. Sci., 35, 1144, 10.1016/j.progpolymsci.2010.04.007 · DOI · Paper page
- Cavalu, 2002, EPR study of non-covalent spin labeled serum albumin and hemoglobin, Biophys. Chem., 99, 181, 10.1016/S0301-4622(02)00182-5 · doi:10.1016/s0301-4622(02)00182-5
- Luten, 2008, Biodegradable polymers as non-viral carriers for plasmid DNA delivery, J. Control. Release, 126, 97, 10.1016/j.jconrel.2007.10.028 · DOI · Paper page
- Pashuck, 2012, Designing regenerative biomaterial therapies for the clinic, Sci. Transl. Med., 4, 160sr4, 10.1126/scitranslmed.3002717 · DOI · Paper page
- Vert, 2011, Degradable polymers in medicine: Updating strategies and terminology, Int. J. Artif. Organs, 34, 76, 10.5301/IJAO.2011.6400 · DOI
- Cavalu, S., Antoniac, I.V., Mohan, A., Bodog, F., Doicin, C., Mates, I., Ulmeanu, M., Murzac, R., and Semenescu, A. (2020). Nanoparticles and Nanostructured Surface Fabrication for Innovative Cranial and Maxillofacial Surgery. Materials, 13. · DOI
- Lee, 2013, Biocompatible gelatin nanoparticles for tumor-targeted delivery of polymerized siRNA in tumor-bearing mice, J. Control. Release, 172, 358, 10.1016/j.jconrel.2013.09.002 · DOI
- Youngren, 2013, STAT6 siRNA matrix-loaded gelatin nanocarriers: Formulation, characterization, and ex vivo proof of concept using adenocarcinoma cells, BioMed Res. Int., 2013, 858946, 10.1155/2013/858946 · DOI
- Syga, 2016, Albumin incorporation in polyethylenimine–DNA polyplexes influences transfection efficiency, Biomacromolecules, 17, 200, 10.1021/acs.biomac.5b01308 · DOI
- Hu, 2017, Versatile functionalization of polysaccharides via polymer grafts: From design to biomedical applications, Acc. Chem. Res., 50, 281, 10.1021/acs.accounts.6b00477 · DOI · Paper page
- Cavalu, 2018, Novel Formulation Based on Chitosan-Arabic Gum Nanoparticles Entrapping Propolis Extract Production, physico-chemical and structural characterization, Rev. Chim., 69, 3756, 10.37358/RC.18.12.6836 · DOI
- Kean, 2005, Trimethylated chitosans as non-viral gene delivery vectors: Cytotoxicity and transfection efficiency, J. Control. Release, 103, 643, 10.1016/j.jconrel.2005.01.001 · DOI · Paper page
- Lin, 2017, Hyaluronic acid conjugated micelles possessing CD44 targeting potential for gene delivery, Carbohydr. Polym., 155, 101, 10.1016/j.carbpol.2016.08.021 · DOI
- Liu, 2012, Synthesis, preparation, in vitro degradation, and application of novel degradable bioelastomers—A review, Prog. Polym. Sci., 37, 715, 10.1016/j.progpolymsci.2011.11.001 · DOI · Paper page
- Reul, 2009, Amine-modified hyperbranched polyesters as non-toxic, biodegradable gene delivery systems, Biomaterials, 30, 5815, 10.1016/j.biomaterials.2009.06.057 · DOI
- Liang, 2015, Optimizing the size of micellar nanoparticles for efficient siRNA delivery, Adv. Funct. Mater., 25, 4778, 10.1002/adfm.201501548 · DOI
- Liu, 2012, Therapeutic delivery of siRNA silencing HIF-1 α with micellar nanoparticles inhibits hypoxic tumor growth, Mol. Pharm., 9, 2863, 10.1021/mp300193f · DOI
- Sun, 2011, Simultaneous delivery of siRNA and paclitaxel via a “two-in-one” micelleplex promotes synergistic tumor suppression, ACS Nano, 5, 1483, 10.1021/nn103349h · DOI · Paper page
- Chen, 2014, Advanced drug and gene delivery systems based on functional biodegradable polycarbonates and copolymers, J. Control. Release, 190, 398, 10.1016/j.jconrel.2014.05.023 · DOI · Paper page
- Kawalec, 2015, Impact of the structure of biocompatible aliphatic polycarbonates on siRNA transfection ability, Biomacromolecules, 16, 769, 10.1021/bm501676p · DOI
- Yang, 2011, Novel biodegradable block copolymers of poly (ethylene glycol)(PEG) and cationic polycarbonate: Effects of PEG configuration on gene delivery, Macromol. Rapid Commun., 32, 1826, 10.1002/marc.201100350 · DOI
- Yang, 2012, Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI, Biomaterials, 33, 1462, 10.1016/j.biomaterials.2011.10.071 · DOI · Paper page
- Shin, 2020, COVID-19 vaccine development and a potential nanomaterial path forward, Nat. Nanotechnol., 15, 646, 10.1038/s41565-020-0737-y · DOI · Paper page
- Malabadi, 2021, Applications of nanotechnology in vaccine development for coronavirus (SARS-CoV-2) disease (COVID-19), Int. J. Res. Sci. Innov., 8, 191
- Drummond, 2008, Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development, J. Pharm. Sci., 97, 4696, 10.1002/jps.21358 · DOI · Paper page
- Ewert, 2010, Cationic liposome–nucleic acid complexes for gene delivery and silencing: Pathways and mechanisms for plasmid DNA and siRNA, Nucleic Acid Transfection, 296, 191, 10.1007/128_2010_70 · DOI
- Felgner, 1987, Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure, Proc. Natl. Acad. Sci. USA, 84, 7413, 10.1073/pnas.84.21.7413 · DOI · Paper page
- 2012, Targeted lipid-based systems for siRNA delivery, J. Drug Deliv. Sci. Technol., 22, 65, 10.1016/S1773-2247(12)50006-7 · DOI
- Karmali, 2007, Cationic liposomes as non-viral carriers of gene medicines: Resolved issues, open questions, and future promises, Med. Res. Rev., 27, 696, 10.1002/med.20090 · DOI · Paper page
- Siafaka, P.I., Üstündağ Okur, N., Karavas, E., and Bikiaris, D.N. (2016). Surface modified multifunctional and stimuli responsive nanoparticles for drug targeting: Current status and uses. Int. J. Mol. Sci., 17. · DOI · Paper page
- Moreira, 2010, Co-encapsulation of anti-BCR-ABL siRNA and imatinib mesylate in transferrin receptor-targeted sterically stabilized liposomes for chronic myeloid leukemia treatment, Biotechnol. Bioeng., 107, 884, 10.1002/bit.22858 · DOI
- Kanamala, 2019, Dual pH-sensitive liposomes with low pH-triggered sheddable PEG for enhanced tumor-targeted drug delivery, Nanomedicine, 14, 1971, 10.2217/nnm-2018-0510 · DOI
- Zangabad, 2018, Stimulus-responsive liposomes as smart nanoplatforms for drug delivery applications, Nanotechnol. Rev., 7, 95, 10.1515/ntrev-2017-0154 · DOI · Paper page
- Dastidar, D.G., and Chakrabarti, G. (2019). Thermoresponsive drug delivery systems, characterization and application. Applications of Targeted Nano Drugs and Delivery Systems, Elsevier. · DOI
- Mollazadeh, 2021, Recent advances in the redox-responsive drug delivery nanoplatforms: A chemical structure and physical property perspective, Mater. Sci. Eng. C, 118, 111536, 10.1016/j.msec.2020.111536 · DOI · Paper page
- Das, S.S., Bharadwaj, P., Bilal, M., Barani, M., Rahdar, A., Taboada, P., Bungau, S., and Kyzas, G.Z. (2020). Stimuli-responsive polymeric nanocarriers for drug delivery, imaging, and theragnosis. Polymers, 12. · DOI · Paper page
- Riley, M.K., and Vermerris, W. (2017). Recent advances in nanomaterials for gene delivery—a review. Nanomaterials, 7. · DOI · Paper page
- Peng, 2014, TAT conjugated cationic noble metal nanoparticles for gene delivery to epidermal stem cells, Biomaterials, 35, 5605, 10.1016/j.biomaterials.2014.03.062 · DOI
- Kundu, 2017, Gold nanoparticles: Their application as antimicrobial agents and vehicles of gene delivery, Adv. Biotechnol. Microbiol., 4, 555
- Rezaei, 2021, A pseudohomogeneous nanocarrier based on carbon quantum dots decorated with arginine as an efficient gene delivery vehicle, Sci. Rep., 11, 13790, 10.1038/s41598-021-93153-4 · DOI
- Zhang, 2012, Quantum dot enabled molecular sensing and diagnostics, Theranostics, 2, 631, 10.7150/thno.4308 · DOI · Paper page
- Ramos-Perez, V., Cifuentes, A., Coronas, N., de Pablo, A., and Borrós, S. (2013). Modification of carbon nanotubes for gene delivery vectors. Nanomaterial Interfaces in Biology, Springer. · doi:10.1007/978-1-62703-462-3_20
- Mebert, 2017, Nanoengineered silica: Properties, applications and toxicity, Food Chem. Toxicol., 109, 753, 10.1016/j.fct.2017.05.054 · DOI · Paper page
- Cavalu, 2013, Microscopic and spectroscopic investigation of bioactive glasses for antibiotic controlled release, J. Mol. Struct., 1040, 47, 10.1016/j.molstruc.2013.02.016 · DOI
- Huang, 2010, The promotion of human malignant melanoma growth by mesoporous silica nanoparticles through decreased reactive oxygen species, Biomaterials, 31, 6142, 10.1016/j.biomaterials.2010.04.055 · DOI
Cited by
Koponen, S., Kokki, E., Tamminen, T., & Ylä-Herttuala, S. (2023) · Frontiers in Drug Delivery · doi:10.3389/fddev.2023.1148795 · Cited by 21
Metadata
- Authors
- Butt, M., Zaman, M., Ahmad, A., Khan, R., Mallhi, T., Hasan, M., Khan, Y., Hafeez, S., Massoud, E., Rahman, M., & Cavalu, S.
- Venue
- Genes
- Publisher
- MDPI AG
- Published
- 2022-07-30
- Volume
- 13
- Issue
- 8
- Pages
- 1370
- ISSN
- 2073-4425 (ISSN-L)
- OpenAlex
- W4289133916
- Cited by
- 210
- References
- 18
- FWCI
- 12.29
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Deanship of Scientific Research at King Khalid University, Abha, Saudi Arabia (No. R.G.P.2/7/43)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Appraisal for the Potential of Viral and Nonviral Vectors in Gene Therapy: A Review. https://app.cochat.ai/papers/10.3390/genes13081370
- The paper
- Butt, M., Zaman, M., Ahmad, A., Khan, R., Mallhi, T., Hasan, M., Khan, Y., Hafeez, S., Massoud, E., Rahman, M., & Cavalu, S. (2022). Appraisal for the Potential of Viral and Nonviral Vectors in Gene Therapy: A Review. Genes. https://doi.org/10.3390/genes13081370
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.